Fate Therapeutics

Biotechnology

Fate Therapeutics develops off-the-shelf cellular immunotherapies derived from iPSCs, creating renewable sources of engineered immune cells. The company's approach could overcome manufacturing limitations of autologous CAR-T therapies. Fate's platform combines cell engineering, iPSC technology, and cancer immunology.

The Biology of Business

Sign up to be notified when the book is available to order.

Notify Me